| Literature DB >> 17448880 |
Rob H Ireland1, Chris M Bragg, Mark McJury, Neil Woodhouse, Stan Fichele, Edwin J R van Beek, Jim M Wild, Matthew Q Hatton.
Abstract
PURPOSE: To demonstrate the feasibility of registering hyperpolarized helium-3 magnetic resonance images ((3)He-MRI) to X-ray computed tomography (CT) for functionally weighted intensity-modulated radiotherapy (IMRT) planning. METHODS AND MATERIALS: Six patients with non-small-cell lung cancer underwent (3)He ventilation MRI, which was fused with radiotherapy planning CT using rigid registration. Registration accuracy was assessed using an overlap coefficient, calculated as the proportion of the segmented (3)He-MR volume (V(MRI)) that intersects the segmented CT lung volume expressed as a percentage of V(MRI). For each patient, an IMRT plan that minimized the volume of total lung receiving a dose > or = 20 Gy (V(20)) was compared with a plan that minimized the V(20) to well-ventilated lung defined by the registered (3)He-MRI.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17448880 PMCID: PMC2713782 DOI: 10.1016/j.ijrobp.2006.12.068
Source DB: PubMed Journal: Int J Radiat Oncol Biol Phys ISSN: 0360-3016 Impact factor: 7.038
Intensity-modulated radiotherapy planning constraints
| Spinal cord | Maximum dose ≤40 Gy |
| Planning target volume | Mean dose 54 Gy; 90% of volume receiving at least 95% of prescription dose |
| Normal tissue | Maximum dose ≤54 Gy |
Summary of patient details
| Patient no. | Staging | Tumor site | Total lung volume (cm3) | Functional lung volume (cm3) | Planning target volume (cm3) |
|---|---|---|---|---|---|
| 1 | T4N2Mx − IIIB | Right upper lobe | 3,930.2 | 2,246.2 | 581.0 |
| 2 | T2N2Mx − IIIA | Right hilum | 3,463.6 | 1,939.3 | 794.0 |
| 3 | T4N2Mx − IIIB | Right hilum | 4,002.1 | 2,689.4 | 747.7 |
| 4 | T3N2Mx − IIIA | Right upper lobe | 5,677.2 | 3,320.5 | 759.1 |
| 5 | T2N0M0 − IB | Left lower lobe | 6,120.1 | 2,899.0 | 240.3 |
| 6 | T2NxMx − IB | Left main bronchus | 5,825.7 | 1,057.5 | 347.4 |
Fig. 1(a) Hyperpolarized 3He magnetic resonance image exhibiting a complete ventilation obstruction for a patient with a tumor in the upper right lobe. (b) Corresponding 1H magnetic resonance image.
Fig. 2Sample registered hyperpolarized 3He magnetic resonance image (right) displayed with the external contour, left and right lung and, for Patient 4, the gross tumor volume (GTV) from the transaxial radiotherapy treatment-planning computed tomography (CT) (left).
Fig. 3The overlap coefficient (Ω) to evaluate image registration for all 6 patients displayed with a sample coronal computed tomography slice.
Mean (SD) of the overlap coefficient used as a measure of registration accuracy calculated for all slices containing CT-defined lung, PTV, and GTV
| Patient no. | Within lung images | Within PTV images | Within GTV images |
|---|---|---|---|
| 1 | 85.5 (15.1) | 82.8 (16.3) | 85.8 (12.2) |
| 2 | 89.6 (5.8) | 89.2 (6.4) | 86.4 (4.7) |
| 3 | 71.9 (14.6) | 66.3 (14.7) | 62.1 (13.0) |
| 4 | 97.0 (1.9) | 97.7 (1.3) | 98.1 (1.0) |
| 5 | 96.7 (2.2) | 96.6 (2.6) | 97.0 (2.7) |
| 6 | 88.2 (8.1) | 90.0 (5.8) | 89.5 (4.2) |
Abbreviations: SD = standard deviation; CT = computed tomography; PTV = planning target volume; GTV = gross tumor volume.
Values are percentages.
Dose parameters for Plan A (minimizing dose to the total lung) and Plan B (minimizing dose to the functional lung)
| Patient no. | FLV20 (%) | TLV20 (%) | MFLD (Gy) | VPTV95/FLV20 | CI | PTV < 95% (%) | Cord max (Gy) | Vol normal tissue ≥ 54 Gy (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plan A | Plan B | Plan A | Plan B | Plan A | Plan B | Plan A | Plan B | Plan A | Plan B | Plan A | Plan B | Plan A | Plan B | Plan A | Plan B | |
| 1 | 32.8 | 32.4 | 31.4 | 31.2 | 15.8 | 14.9 | 3.0 | 3.0 | 0.85 | 0.75 | 2.2 | 4.1 | 39.5 | 39.6 | 0.09 | 0.35 |
| 2 | 19.4 | 18.8 | 23.2 | 22.8 | 12.3 | 12.2 | 4.6 | 4.8 | 0.79 | 0.82 | 9.9 | 8.9 | 35.7 | 36.5 | 0.16 | 0.13 |
| 3 | 28.1 | 24.3 | 27.6 | 23.9 | 13.3 | 12.5 | 3.5 | 3.9 | 0.86 | 0.74 | 2.2 | 5.2 | 38.1 | 40.0 | 0.17 | 0.47 |
| 4 | 27.1 | 23.5 | 27.1 | 24.7 | 14.2 | 13.2 | 3.0 | 4.1 | 0.76 | 0.85 | 18.8 | 3.4 | 40.0 | 40.0 | 0.02 | 0.10 |
| 5 | 7.6 | 5.0 | 11.7 | 9.0 | 5.2 | 5.0 | 12.9 | 18.9 | 0.86 | 0.79 | 2.6 | 5.2 | 25.8 | 30.1 | 0.01 | 0.07 |
| 6 | 33.9 | 28.8 | 19.0 | 18.3 | 16.3 | 14.0 | 2.9 | 3.4 | 0.85 | 0.88 | 1.4 | 2.4 | 22.0 | 32.4 | 0.07 | 0.05 |
| Median | 27.6 | 23.9 | 25.2 | 23.4 | 13.8 | 12.9 | 3.3 | 4.0 | 0.85 | 0.81 | 2.4 | 4.6 | 36.9 | 38.1 | 0.08 | 0.12 |
| 0.028 | 0.028 | 0.028 | 0.043 | 0.462 | 0.463 | 0.043 | 0.116 | |||||||||
Abbreviations: FLV20 = percentage of the functional lung receiving ≥20 Gy; TLV20 = percentage of the total lung receiving ≥20 Gy; MFLD = mean dose to the functional lung; VPTV95/FLV20 = ratio of the percentage volume of the planning target volume (PTV) receiving at least 95% of the prescription dose (VPTV95) to the functional lung V20; CI = conformity index; PTV <95% = percentage of the PTV receiving less than 95% of the prescribed dose; Cord max = maximum spinal cord dose; Vol normal tissue ≥ 54Gy = percentage of the normal tissue (non-PTV) receiving ≥54 Gy.